INTRODUCTION
In striated muscle, the dihydropyridine receptor (DHPR, which is a membrane voltagesensing protein as well as a Ca 2+ -entry channel on transverse (t)-tubule membranes) is activated by membrane depolarization, which allows the ryanodine receptor (RyR, which is an internal Ca 2+ -releasing channel on the sarcoplasmic reticulum (SR) membrane) to release Ca 2+ ions from the SR into the myoplasm, and finally induces muscle contraction. This process is called excitation-contraction (EC) coupling (1) (2) (3) . In addition to the central theme of EC coupling, canonical-type transient receptor potential cation channel 3 (TRPC3, which is a Ca 2+ -entry channel on sarcolemmal membrane) is required for the full gain of skeletal EC coupling (duration and maintenance) (4) . Collaterally, channels mediating store-operated Ca 2+ -entry (SOCE) (5, 6) are needed for the sustained presence of a certain concentration of myoplasmic Ca 2+ ions in skeletal muscle cells: for example, Orai1, TRPC1 and TRPC4 (7) (8) (9) (10) (11) . Junctional membrane complexes (JMC), which are known as diad or triad junctions in striated muscle and where t-tubules and the SR membranes are juxtaposed, provide the structural context for proper arrangement of the Ca 2+ channels mentioned above and for functionally efficient couplings among the Ca 2+ channels (12, 13) .
Junctophilins (JPs) contribute to the formation of JMC in excitable cells, including muscle cells, by interacting with both plasma and endoplasmic reticulum (ER) membranes (in muscle cells, t-tubule membranes via their Nterminal MORN motifs (highly conserved membrane occupation and recognition nexus) and SR membranes via the C-terminal transmembrane domain) (12) (13) (14) (15) . Thus far, four JP subtypes have been identified: JP1 in skeletal muscle; JP2 abundantly in all muscle types (skeletal, cardiac, and smooth muscles); and, JP3 and JP4 in the brain (14, 16, 17) . JP1 or JP2 knock-out in mice induces disorganized JMC and disrupted Ca 2+ homeostasis in skeletal muscle or cardiomyocytes, and finally neonatal or embryonic death, respectively (12, 13, 18) . JP1 and JP2 knock-down in mouse skeletal muscle fibers leads to decreases in intracellular Ca 2+ release and SOCE and the disorganization of JMC (19). TRPC3 knock-down in mouse skeletal myotubes involves an increase in JP1 expression and a decrease in Ca 2+ transients from the SR (4) , and the N-terminal region of JP2 (a.a. 143-234) interacts with TRPC3 in skeletal myotubes (20, 21) . In the case of the neuronal JP isoforms (JP3 and JP4), the only information that has been reported involves a mouse model for neurodegenerative Huntington's disease-like-2 disorder that showed a decrease in JP3 expression due to changes in the genetic level (22) .
Hypertrophic cardiomyopathy (HCM) in humans, a significant cause of sudden cardiac death, is a genetic disorder related to mutations of muscle genes such as those encoding actin, myosin, tropomyosin, troponin, Z-disc proteins, and others (23) . Down-regulation of JP2 has been observed in hypertrophic and dilated cardiomyopathic mouse models (24) , in a pressure overload-induced cardiac hypertrophic rat model (25) , and over the progression of hypertrophy into heart failure in a rat model (26) . Indeed, five JP2 single mutants (S101R, Y141H, S165F, R436C, and G505S) have been found in HCM patients (27, 28) , which strongly supports the idea that JP2 is one of the HCM-related proteins. Among the five mutants of JP2, Y141H and S165F significantly disrupt Ca 2+ signaling when expressed in HL-1 atrial cardiomyocytes (27) . In mouse skeletal myotubes, S165F also induced hypertrophy and a reduced gain in EC coupling, which is related to the phosphorylation of S165F by protein kinase C (PKC) (29) . However, the effect(s) of the four other human HCM-related JP mutants on skeletal muscle have not been addressed, although JP2 is an abundant protein in both skeletal and cardiac muscles. Therefore, in the present study, Y141H, a JP2 mutant associated with human HCM and one of two mutants causing severely disrupted Ca 2+ signaling in cardiomyocytes, was expressed in mouse skeletal myotubes in order to examine the effect(s) of Y141H on skeletal muscle function and Ca 2+ signaling. imaging experiment or the immunocytochemistry), or 6-well plates (for the TEM observation) coated with Matrigel (BD Biosciences). When myoblasts reached ~70% confluence, the growth medium was replaced with differentiation medium (5% heat-inactivated horse serum and low-glucose Dulbecco's Modified Eagle's Medium (DMEM) without growth factors instead of 20% FBS and F-10 Nutrient Mixture in the growth medium), and the myoblasts were placed in an 18% CO 2 incubator to induce differentiation. After three days of culture in differentiation medium, the myoblasts were transfected with cDNA encoding wild-type JP2, Y141H, or S165F in an expression vector (pCMS-RFP) for 4 hrs. Construction of the cDNAs was previously described (27) . A mixture of 30 μl of FuGENE6 (Roche) and 20 μg cDNA per 10-cm dish or the same ratio of the components in the wells of 96-well or 6-well plates was used for transfection. Fully differentiated myotubes on differentiation day 5 (at 36 hrs post-transfection) were subjected to further experiments. Approximately 40% of the myotubes had been transfected by the cDNA (estimated by a red fluorescent protein (RFP) signal from a separate promoter of the expression vector). For the cell migration assay, premature myotubes at 16 hrs post-transfection were used.
HL-1 atrial cardiomyocytes were plated on 10-cm dishes coated with fibronectin (Sigma) and gelatin (Fisher Scientific) and were maintained in Claycomb media (JRH Biosciences) supplemented with 10% FBS, 1% penicillin/streptomycin, 0.1 mM norepinephrine, and 2 mM L-glutamine. HL-1 cardiomyocytes were transfected with cDNA encoding wild-type JP2 or Y141H in the expression vector as described above. At 36 hrs post-transfection, HL-1 cardiomyocytes were subjected to the cell lysate preparation or the image capture. Approximately 50% of the HL-1 cardiomyocytes had been transfected (estimated by RFP signal). (GenBank accession number NM_175423.3) were selected using a siRNA design software, siDirect (32) , and are summarized in Table 2 . The siRNAs were synthesized by a company (Genolution, Seoul, Korea), and a scrambled siRNA was used as a negative control. Premature myotubes transfected with cDNA encoding Y141H were transfected with one of the siRNAs on differentiation day 4 in a mixture containing 600 μl of low-glucose DMEM, 60 μl of a transfection reagent (X-tremeGENE, Roche), and 200 nM of the specific synthetic siRNAs for 3 hrs according to the manufacturers' protocols (Roche and Genolution). After the transfection, fully differentiated myotubes on differentiation day 5 were subjected to further experiments. The transfection efficiency assessed by a cell viability assay using a siRNA for a homeogene supplied by Genolution was approximately 95%. Optimal quantities of X-tremeGENE and siRNA and transfection frequencies were defined by evaluating the strongest effect of siRNAs.
Single myotube
Reverse transcription and quantitative real-time PCR (RT-PCR and qPCR) -Total RNA was isolated from myotubes using QIAshredder and RNeasy Mini Kit (Qiagen) according to the manufacturer's protocols. RT-PCR and qPCR were performed on SmartCycler System (Cephid) using One-Step kit (TaKaRa). Briefly, the following reaction mixture was prepared on ice: 12.5 μl of 2X One-Step SYBR RT-PCR buffer III, 2.5 U of Ex Taq HS, 0.5 μl of PrimeScript RT enzyme Mix II, 0.2 μM of each PCR forward or backward primer, and 50 ng of total RNA (25 μl of total reaction volume). Reaction conditions were 1 cycle of 42 °C for 5 min and 95 °C for 10 sec for RT-PCR, 50 cycles of 95 °C for 5 sec and 60 °C for 20 sec for qPCR, and incubation at 60 °C for 1 min for dissociation step. After the reaction was completed, signal verification was conducted with the amplification and melting curves using a comparative threshold cycle method from SmartCycler System (Cephid). A mean quantity was calculated from duplicated or triplicated qPCR reactions for each sample, and this quantity was normalized to the endogenous control gene, β-actin. Primers used for the qPCR are described in Table 2 .
Immunocytochemistry -Myotubes were fixed in cold methanol (-20 °C) for 15 min and permeabilized with 0.05% Tween 20 in phosphatebuffered saline (PBS) for 1 min. After blocking myoblasts with 2% normal goat serum (NGS, Jackson ImmunoResearch) in PBS, the myoblasts were incubated with anti-STIM1 or anti-Orai1 antibody (10 μg/ml) for 3 hrs at room temperature, washed with 2% NGS in PBS for 10 min, incubated with a Cy-3-conjugated anti-mouse (1:500, Jackson ImmunoResearch) or FITC-conjugated anti-rabbit secondary antibody (1:500, Sigma-Aldrich) for 45 min at room temperature, and visualized with an inverted fluorescence microscope using a x40 objective lens (ECLIPSE Ti, Nikon) equipped with a monochrome camera (ProgRes MF, JENOPTIK Optical Systems, Inc.).
Preparation
of cell lysate and immunoprecipitation assay -Myotubes or HL-1 cardiomyocytes were solubilized in a lysis buffer (1% Triton X-100, 10 mM Tris-HCl (pH 7.4), 1 mM Na 3 VO 4 , 10% glycerol, 150 mM NaCl, 5 mM EDTA, and protease inhibitor mixture (Roche)) overnight at 4 °C with gentle mixing (300 µl of the lysis buffer to the myotubes in a 10-cm dish). The solubilized lysate was then centrifuged at 1,500 g for 30 sec to remove insoluble matter. For immunoprecipitation assay, the solubilized myotube lysate (800 μg of total protein) was incubated with anti-phosphoserine antibody (20 μg/mg, Chemicon International) at 4 °C overnight, followed by incubation with Protein G-Sepharose beads (Amersham Biosciences) at 4 °C for 4 hrs. The beads were washed five times with PBS. Proteins bound to the beads were eluted by boiling in a sodium dodecyl sulfate (SDS) sample buffer and were subjected to immunoblot assay.
Immunoblot assay -Myotube or HL-1 cardiomyocyte lysate (30 μg of proteins), or immunoprecipitants were subjected to 8 or 10% SDS-polyacrylamide gel electrophoresis, and the proteins on the gel were stained with coomassie brilliant blue or transferred onto a polyvinylidenefluoride membrane at 100 V for 2 hrs. The membrane was blocked by 5% non-fat milk dissolved in PBS for 1 hr, incubated with one of the primary antibodies overnight at 4 °C, washed three times with PBS containing 0.1% Tween 20 (PBST), and then incubated with one of the corresponding horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-donkey secondary antibodies (1:2000, Jackson ImmunoResearch) for 45 min at room temperature. The membrane was washed three times with PBST and developed using SuperSignal ultrachemiluminescent substrate (Pierce). An anti-DHPR antibody (against α1 subunit of DHPR, 1:1,000) was obtained from Affinity BioReagents; an anti-RyR1 antibody (1:2,000) was obtained from Drs. J. Airey and J. Sutko (Developmental Studies Hybridoma Bank); anti-Orai1 and anti-STIM1 antibodies (1:500) were obtained from abcam; and, anti-JP2 (1:1,000), anti-TRPC1 (1:800), anti-TRPC3 (1:800), anti-TRPC4 (1:800), anti-TRPC6 (1:800), anti-PKC (1:500), anti CaMK II (1:1,000), anti-CnA (1:1,000), and anti-α-actin (1:1,000) antibodies were obtained from Santa Cruz Biotechnology.
Cell migration assay -Cell migration assay was performed as previously described (33) . Briefly, premature myotubes transfected with cDNA encoding wild-type JP2 or Y141H were scraped off with a pipette tip to make a long and thin acellular area. Images of the acellular area with the adjacent premature myotubes surrounding it were captured. After 12 hrs of scraping, images of the same acellular area were captured to evaluate the migration of premature myotubes to the acellular area.
Transmission electron microscopy (TEM) -For TEM observations, myotubes were fixed in a fixative solution (4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4) overnight at 4 °C. The fixed myotubes were washed with the phosphate buffer and post-fixed with 1% osmium tetroxide in the phosphate buffer for 1 hr at room temperature. The myotubes were dehydrated with ethyl alcohol and acetone, and embedded in epoxy resin (Epon 812). Ultra-thin sections (70-80 nm) were obtained using an ultramicrotome (Ultracut UCT ultramicrotome, Leica). The sections were double-stained with uranyl acetate and lead citrate, and examined under a transmission electron microscope (JEM1010, JEOL Ltd.) at 60 kV.
Statistical analysis -Results are presented as the mean ± S.E. for the number of myotubes shown in parentheses in Table 1 . Values were normalized to the mean value of those from corresponding controls. Significant differences were analyzed using a paired t-test (GraphPad InStat, v2.04). Differences were considered to be significant at p < 0.05. Graphs were prepared using Origin v7.
RESULTS

Y141H mutation of JP2 induces hypertrophy in skeletal myotubes
Y141 in JP2 is one of the residues comprising the first group of MORN motifs (Fig.  1A) . A human HCM-associated JP2 mutant, Y141H, was expressed in mouse primary skeletal myotubes as described in Experimental Procedures. Myotube lysate from the plates transfected with cDNA encoding either wild-type JP2 or Y141H showed approximately twice as much JP2 protein as myotube lysate from the untransfected plates (Fig. 1B) . Considering the heterogeneous nature of transient transfection and the approximately 40% transfection efficiency (estimated by the RFP signals, Fig. 1C ), an average amount of total JP2 proteins (both endogenous and exogenous) in the transfected myotubes would be 3.5-fold compared with that in untransfected myotubes. Interestingly, a significant increase in diameter was found in Y141H-expressing myotubes compared with wildtype controls (increased by 1.53 ± 0.13 fold) ( Fig.  1D and Table 1 ). These results indicate that a single mutation in JP2 at Y141 induced hypertrophy in skeletal myotubes, similar to the hypertrophy observed in the cardiac muscle from HCM patients.
A reduced gain of EC coupling and abnormal JMC in Y141H-expressing skeletal myotubes
To measure myoplasmic Ca 2+ transients per unit area during EC coupling, KCl (inducing membrane depolarization) was applied to Y141H-expressing myotubes. Y141H-expressing myotubes showed a significant decrease in myoplasmic Ca 2+ transients with no change in the activation slope compared with wild-type controls ( Fig. 2A and Table 1 ). Since Ca 2+ transients would be expected to be larger if the size of the myotubes increased, the net decrease of Ca 2+ transients during EC coupling in Y141H-expressing myotubes might possibly be larger than that presented in Fig. 2A . The expression level of the α1 subunit of DHPR (the membrane voltagesensing and Ca 2+ -conducting pore-forming subunit of DHPR) or RyR1 was not significantly changed ( Fig. 5B) , suggesting that the decrease in myoplasmic Ca 2+ transients during EC coupling was not simply due to a reduction in DHPR or RyR1 expression.
There are two possible explanations for the reduced gain of EC coupling in the Y141H-expressing myotubes. (1) RyR1 activity might be reduced and result in a reduced gain in EC coupling, or (2) the spatial arrangement of RyR1 and DHPR might not be complete enough to induce the full gain of EC coupling. To test the first possibility, we measured myoplasmic Ca 2+ transients per unit area in response to a direct RyR1 agonist -caffeine. Y141H-expressing myotubes showed no significant change in myoplasmic Ca 2+ transient in response to caffeine, and the activation slope of the Ca 2+ transients was comparable to that of wild-type controls ( Fig. 2B and Table 1 ), suggesting that the reduced gain of EC coupling was not due to a change in RyR1 activity. In accordance with the unchanged RyR1 activity, there was also no significant change in the amount of SR-stored Ca 2+ (estimated by treatment with 10 µM cyclopiazonic acid (CPA), an inhibitor of the SR Ca 2+ -uptake pump) (Fig.  2C) .
To test the latter possibility, myotubes expressing wild-type JP2 or Y141H were examined by transmission electron microscopy (TEM). Unlike well-organized JMC in wild-type controls, it is of interest that abnormal JMC (multi-layered tubule structures) was frequently found between two SRs or near the SR in Y141H-expressing myotubes (Fig. 3 , right, indicated by arrowheads). Considering that paired or close arrangements of RyRs and DHPR on JMC are a necessary factor for authentic skeletal or cardiac EC coupling, respectively, the multi-layered abnormal tubule structures could be one of the causes for the reduced gain of EC coupling in Y141H-expressing myotubes.
Hypertrophy, a reduced gain of EC coupling, and abnormal JMC are dominantnegative effects of the Y141H mutant over the native JP2, because native JP2 is endogenously expressed in skeletal muscle.
An increase in resting myoplasmic Ca 2+ levels in Y141H-expressing skeletal myotubes
To determine the molecular mechanism(s) underlying the reduced gain of EC coupling in Y141H-expressing myotubes, resting myoplasmic Ca 2+ levels were examined. Y141H-expressing myotubes maintained a significantly higher resting myoplasmic Ca 2+ level per unit area than wild-type controls (Fig. 4A, and Table 1 , an increase of approximately 70%). The absolute amount of total Ca 2+ ions in the myoplasm of a single Y141H-expressing myotube is supposed to be much greater than that of wild-type controls. Because Y141H-expressing myotubes were hypertrophied, the absolute myoplasmic volume of the hypertrophic myotubes (in terms of three dimensions) was much greater than that of wildtype controls.
To find possible upstream or downstream factors for the elevation of the resting myoplasmic Ca 2+ level in Y141H-expressing myotubes, first, Ca 2+ -entry at rest was measured using Mn 2+ quench experiments. The decay rate in fura-2 fluorescence in Y141H-expressing myotubes after Mn 2+ exposure was little decreased but not significantly different from that of the wild-type controls (Fig. 4B) , suggesting that a change in Ca 2+ -entry at rest was not a reason for the increase in resting myoplasmic Ca 2 level. Second, the expression of Ca 2+ -dependent protein kinases or phosphatases, which are known to be involved in HCMs, was examined by immunoblot assay. PKC expression was significantly increased in Y141H-expressing myotubes compared with wild-type controls (Fig. 5A) . Therefore, it is likely that the reduced gain of EC coupling in Y141H-expressing myotubes would result from change(s) in PKCmediated signaling.
On the other hand, Y141 itself is an irrelevant mutant to phosphorylation by PKC, but it is possible that the mutation at Y141, which is an adjacent residue to S165 (the substantial and only phosphorylation site of JP2 by PKC, Supplemental data 1,), could mask the phosphorylation at S165 by blocking the accessibility of PKC to S165. Immunoprecipitation of myotube lysate with antiphosphoserine antibody, followed by immunoblot assay of the immunoprecipitates with anti-JP2 antibody showed that the total amount of phosphorylated JP2 proteins at the serine residue was not altered by the expression of Y141H (Supplemental data 2). Therefore, it seems that Y141H was not directly affected by the increased PKC expression.
An increase in SOCE mediated by Orai1 in Y141H-expressing skeletal myotubes
Third, the expression level of Ca 2+ -conducting channels was examined by immunoblot assay using myotube lysate from Y141H-expressing myotubes (Fig. 5B) . As mentioned earlier, the expression levels of the two major EC-coupling-mediating Ca 2+ channels (DHPR and RyR1) were not changed. The expression of five extracellular Ca 2+ -entry channels that are known to be expressed in skeletal muscle (TRPC1, TRPC3, TRPC4, TRPC6, and Orai1) was also examined. Among them, interestingly, Orai1 (a major protein responsible for SOCE in response to SR Ca 2+ -depletion in skeletal muscle) was significantly up-regulated (approximately 4.8-fold considering 40% transfection efficiency) with no change in the expression level of its functional partner, STIM1 (a Ca 2+ -sensing protein on SR membrane). As shown in Y141H-expressing myotubes, Orai1 expression was also increased in Y141H-expressing HL-1 atrial cardiomyocytes (Fig. 5C ) as well as cell size (i.e., hypertrophy, Fig. 5D ).
To test whether the increased Orai1 expression also affected an Orai1-mediated functional event (i.e., SOCE), the SR of Y141H-expressing myotubes was depleted by treatment with CPA in the absence of extracellular Ca 2+ , and then 2 mM Ca 2+ was applied to the extracellular bath in order to induce SOCE. As expected, SOCE was significantly increased (Fig.  6A , Table 1 , an increase of approximately 88%). In addition, puncta formed by oligomerized STIM1 and Orai1 (the necessary organization for SOCE) were also more frequently found in Y141H-expressing myotubes (Fig. 6B) . Therefore, increased SOCE due to the increased expression of Orai1 could be one reason for the elevated resting myoplasmic Ca 2+ level in Y141H-expressing myotubes.
To confirm that the increase in size in Y141H-expressing myotubes was mediated by the increased Orai1 expression, Orai1 was knocked down in Y141H-expressing myotubes. To interfere with the mRNA of Orai1, nine different siRNAs for Orai1 were designed (shown in Table  2 ) and subjected to transfections to Y141H-expressing myotubes as described in Experimental Procedures. Quantitative real-time PCR (qPCR) analysis of cDNA from each transfected myotube batch showed that #4 siRNA was the most efficient in knocking down Orai1 (77.5 ± 1.5% reduction in mRNA and approximately 94% reduction in protein, Figs. 7A and 7B, and Supplemental data 3). Therefore, #4 siRNA was subjected to further experiments. Premature myotubes transfected with cDNA encoding Y141H were transfected with #4 siRNA on differentiation day 4. Transfection efficiency for Y141H was visualized by the presence of RFP signals (Fig. 7C, right-hand panel) , and transfection efficiency for siRNA was assessed by a cell viability assay using a siRNA for a homeogene described in Experimental Procedures. Y141H-expressing and Orai1 knock-down myotubes showed no significant change in diameter (Fig. 7C , white arrows in the left-hand panel) and resting myoplasmic Ca 2+ level (Fig.  7D ) compared with either untransfected control or scrambled siRNA-or #4 siRNA-transfected control. Therefore, the increased Orai1 expression resulted in increases in both size and resting myoplasmic Ca 2+ level in Y141H-expressing myotubes.
DISCUSSION
Hypertrophy in skeletal myotubes caused by two human HCM-associated JP2 mutants, Y141H and S165F, involves altered Ca 2+ signaling via different proteins
In summary, we examined the effect of the Y141H mutant of JP2 on skeletal muscle. Consistent with the S165F mutant of JP2 (29), a dominant-negative inhibition by Y141H over the native JP2 resulted in several consequences, including significant myotube hypertrophy, a decreased gain of EC coupling, and an increase in the resting myoplasmic Ca 2+ level. Different from S165F, Y141H-expressing myotubes involved two new characteristics: abnormal JMC and an increase in SOCE via Orai1.
It is well known that various hypertrophic stimuli elevate intracellular Ca 2+ levels, which mediate the progression of cardiac hypertrophy via various routes: for example, activation of Ca 2+ -related proteins (34) . In accordance with this, the expression of Y141H in skeletal myotubes induced hypertrophy with a reduced gain of EC coupling and an elevated resting myoplasmic Ca 2+ level. However, in order to reach the hypertrophic phenomena, a different sub-route utilizing different proteins was involved in Y141H-expressing myotubes compared with S165F. First, unlike S165F, which is an unphosphorable mutant by PKC (29) , the phosphorylation level of Y141H by PKC was about the same as that of wild-type JP2 (Supplemental data 2). Second, Y141H-expressing myotubes showed an increase in Orai1 expression accompanying increases in both physiological SOCE and morphological puncta formation. However, there was no change in Orai1 expression in S165F-expressing myotubes (Supplemental data 4), suggesting that Orai1 is a skeletal hypertrophy-mediating protein by Y141H but not by S165F. Interestingly, Orai1 seems to also be a hypertrophy-mediating protein in cardiac muscle, because Orai1 knock-out in neonatal rat ventricular cardiomyocytes diminished cell size and even completely blocked phenylephrine-mediated hypertrophy (35) . In addition, in the present study, HL-1 atrial cardiomyocytes expressing Y141H showed increases in both Orai1 expression and cell size.
On the other hand, PKC has reportedly suppressed SOCE by the phosphorylation of Orai1 in HEK293 cells (36) . In the present study, the increased expression of PKC in Y141H-expressing myotubes may be a compensatory action for the increased Orai1 expression. 
Roles of junctophilin-2 in muscle hypertrophy
Y141 and S165 residues of JP2 play different roles in the Ca 2+ signaling of skeletal muscle Y141 in JP2 is one of the residues comprising MORN motifs that interact with ttubule membranes in order to 'structurally' form JMC, and JMC allows EC coupling-mediating and -regulating proteins to be positioned close enough for functionally efficient cardiac and skeletal EC coupling (2, 12, 13) . In the present study, a mutation at Y141 substantially induced abnormal JMC and possibly subsequent reduction in the gain of EC coupling in skeletal myotubes. On the other hand, S165 of JP2 is an irrelevant residue to MORN motifs by locating in the joining region between two groups of MORN motifs (Supplemental data 1). Secondary structure prediction for JP2 using a program, Jpred3 Incorporating Jnet (37) , suggests that the region containing S165 forms a short α-helix (151 to 166 residues) (21) . The region covering the short α-helix confers TRPC3-binding abilities on JP2 (20,21). A single mutation at S165 greatly diminishes the binding ability of JP2 to TRPC3 (29) . Taken together, it seems that Y141 participates in the formation of complete JMC as a building block (structural integrity for Ca 2+ signaling), and S165 is one of the tuning buttons for complete connections among EC couplingmediating and -regulating proteins on JMC (functional integrity for Ca 2+ signaling). Therefore, it seems that Y141 and S165 of JP2 play different roles in the Ca 2+ signaling of skeletal muscle, and the location of mutations in JP2 could be a code for discriminating among several sub-routes of hypertrophic pathways in skeletal muscle.
Authentic JMC in the presence of JP2 are key structures for striated muscle function Y141H-expressing myotubes showed abnormally multi-layered tubule structures near the SR instead of authentic JMC. Under this circumstance, the rate of physical coupling between DHPR and RyR1 could be decreased (more orphaned RyRs unoccupied by DHPR) due to the widespread distribution of the limited numbers of DHPRs on the wider tubule membranes. The possibility for the presence of more orphaned RyRs in Y141H-expressing myotubes was strongly supported by the reduced gain of EC coupling unaccompanied by a change in RyR1 activity, in DHPR and RyR1 expression, and in SR Ca 2+ content.
In the case of cardiac muscle cells, the efficiency of EC coupling would also be lowered due to abnormally multi-layered tubule structures that pose physical obstacles to the diffusion of Ca 2+ ions to RyR2. Indeed, a reduced gain of EC coupling due to dispersion of JMC without altered Ca 2+ channel expression or SR Ca 2+ content (like Y141H-expressing myotubes in the present study) was reported in cardiomyocytes from heart failure or cardiac hypertrophic rat models and from a ventricular arrhythmia mouse model (38) (39) (40) . From the viewpoint of JP2, a gradual reduction in JP2 expression and contractility was found in ventricular myocytes from the early hypertrophic rat (26) , in hypertrophic and dilated cardiomyopathic mouse models (24) , and in a pressure overload-induced cardiac hypertrophic rat model (25) . Clinically, cardiac tissue from HCM patients showed a reduction in JP2 expression, and JP2 knock-down in HL-1 cardiomyocytes resulted in hypertrophy with reduced gain of EC coupling (41) . Therefore, in both skeletal and cardiac muscles, abnormal JMC due to the reduced expression of native JP2 or the presence of mutated JP2s could be an ultrastructural substrate for abnormal muscle functions.
The hypertrophy in Y141H-expressing myotubes could be related to faster migration of premature myotubes, possibly due to the increased SOCE Migration and fusion (the first phase of fusion) of myoblasts are key steps in the myogenesis and regeneration of skeletal muscle. In order to form long and multi-nucleated myotubes during skeletal muscle differentiation, myoblasts migrate in all directions and form prefusion alignment before actual fusion (42) . The second phase of fusion, which is called maturation in normal physiology or hypertrophy in abovenormal physiology, permits premature myoblasts to become longer and thicker. It is interesting that more fusion was observed in Y141H-expressing myotubes than wild-type controls during differentiation under an electron microscope, which was not previously observed in S165F-expressing myotubes. To find the possible reason(s) for this result, migrations of premature myotubes were examined on differentiation day 3, when premature myotubes vigorously migrate in order to form longer and thicker mature myotubes. Y141H-expressing premature myotubes migrated to an acellular area faster than wild-type controls (Supplemental data 5). Vascular smooth muscle cells with a reduced SOCE by the knock-down of STIM1 and Orai1 showed the inhibition of cell migration (43) . C2C12 cells (a mouse myoblast cell line) with a reduced SOCE by TRPC1 knockdown showed a slow-down in myotube formation (33) . In the present study, Y141H-expressing myotubes showed increases in both Orai1 expression and SOCE. According to previous reports and our results in the present study, the increased SOCE seems to be related to higher migration efficiency and hypertrophy in Y141H-expressing myotubes.
Orai1 and SOCE are effectors of mutated JP2-bearing striated muscle hypertrophy
As addressed earlier, STIM1 is a sensor protein for ER/SR Ca 2+ -depletion (5, 6, 44) . Ca 2+ -depletion causes STIM1 to be oligomerized and redistributed to the ER/SR membrane near the cellular periphery, and to interact with Orai1 -which is called puncta (a prerequisite for SOCE via Orai1) (5, 6, 9, 10, 44) . In particular, puncta in skeletal muscle were pre-assembled naturally during the differentiation of myoblasts to myotubes (10) . In the present study, fully differentiated mouse primary skeletal myotubes also showed pre-assembled puncta (ready-to-go forms, which is a prerequisite for SOCE via Orai1 but not the necessary and sufficient condition for SOCE). Skeletal and cardiac muscles seem to take advantage of their specialized JMC (triad or diad) to achieve the pre-assembled puncta, and these ready-to-go puncta are compatible with the rapid activation of SOCE in rat skeletal muscle fibers (activation in less than 1s (45)). Y141H-expressing myotubes showed more pre-assembled puncta than wild-type controls, and there are two potential mechanisms for this. One is that the abnormally multi-layered tubule structure in Y141H-expressing myotubes may increase the chance of a juxtaposed arrangement of tubules and SR membranes, which favors pre-assembly of the puncta. The other is that the increased Orai1 expression in Y141H-expressing myotubes might act as a puncta-tropic factor through mass action: a quantitative gain increases qualitative gain. In either case, more pre-assembled puncta and subsequently more SOCE could contribute to the elevation of resting myoplasmic Ca 2+ level in Y141H-expressing myotubes. If this is the case, Orai1 and SOCE could be effectors of hypertrophic phenomena in striated muscle.
In vascular smooth muscle and in HEK293 cells, STIM1 strongly suppresses Ca V 1.2 while activating Orai1 (a reciprocal control of Ca V 1.2 and Orai1 by STIM1 at the same time) (46) . A preponderance of Orai1 might induce more STIM1-Orai1 interaction (i.e., more SOCE) and more suppression of DHPR (Ca V 1.1, the skeletal isoform of Ca V 1.2, i.e., less EC coupling) as shown in Y141H-expressing myotubes. It is, therefore, possible that another type of retrograde signaling from the SR to the t-tubule membrane via STIM1 would exist in striated muscle.
Overall, JP2 has recently emerged as a hypertrophy-related protein by studies on HCM patients and various hypertrophic animal models. In the present study, we suggest how the Y141H mutant of JP2 is involved in skeletal muscle hypertrophy at the cellular level, and that an increase in SOCE via Orai1 could be a novel factor in the increased myoplasmic Ca 2+ levels of JP2-related muscle hypertrophy. It is not currently clear whether the JP2 mutation plays a primary or secondary role in the development of hypertrophy. However, the present study suggests that JP2 could be a new molecular target for the regulation of abnormal Ca 2+ homeostasis in striated muscle hypertrophy, and provides insight into possible varieties of sub-cellular mechanisms by which this mutant causes cardiac hypertrophy in humans bearing this mutation. Myotubes expressing wild-type or Y141H were visualized using TEM observations. Areas in numbered boxes were enlarged. In Y141H, the images in boxes 2 and 3 are considered as 90° horizontally rotated and tilted images of box 1, respectively. mM Ca 2+ was added to the extracellular bath in order to induce SOCE. A representative trace for each group is presented. Y141H-expressing myotubes showed a significantly increased SOCE. SOCE per unit area was summarized as histograms (the peak area was normalized to the mean value of those from wild-type controls). *Significant difference compared with wild-type (p < 0.05). B, Myotubes were doublestained with anti-Orai1 and anti-STIM1 antibodies. Merged images show more puncta in Y141H-expressing myotubes. Boxed areas in the merged images were enlarged in the right-hand panels. DIC, differential interference contrast microscopy.
FIGURE 7. No hypertrophic phenomenon in Y141H-expressing myotubes by knocking down Orai1.
To interfere with the mRNA of Orai1, myotubes were transfected with the siRNAs for Orai1 or scrambled control as described in Experimental Procedures. A, qPCR analysis showed that Orai1 mRNA was reduced by 77.5 ± 1.5% by #4 siRNA transfection compared with untransfected or scrambled controls.
The data are the mean ± S.E. of duplicated independent experiments. Significant reduction in the mRNA level of Orai1 was indicated by a white asterisk. For the results of other siRNAs, see Table 2 and 
TABLE 1.
Roles of junctophilin-2 in muscle hypertrophy
Properties of Y141H-expressing myotubes. Values were normalized to the mean value of those from myotubes expressing wild-type JP2.
Values are represented as the mean ± S.E. for the number of myotubes shown in parentheses. Values for resting myoplasmic Ca 2+ level, and KCl, caffeine, and CPA responses of wild-type and untransfected myotubes were adopted from our previous report (29) . *Significant difference vs. wild type (p < 0.05).
Wild-type Untransfected Y141H
Diameter of myotubes 1.00 ± 0.06 (62) 
